Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ocular Therapeutix (OCUL) Stock Price
News articles about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.8393866479787 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Ocular Therapeutix™ Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality (finance.yahoo.com)
- Erland Construction Completes Ocular Therapeutix Inc. New Headquarters – Banker & Tradesman (bankerandtradesman.com)
- Ocular Therapeutix Inc (OCUL) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
- Ocular Therapeutix, Inc., (NASDAQ: OCUL) – Manage Your Risk Before Making Any Investment Decision – Stock Watch (stocksnewstimes.com)
Several equities research analysts have recently issued reports on OCUL shares. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $21.00 target price on shares of Ocular Therapeutix in a research note on Monday, September 25th. Guggenheim started coverage on shares of Ocular Therapeutix in a research note on Monday, October 23rd. They issued a “buy” rating and a $12.00 target price for the company. Zacks Investment Research cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. Ocular Therapeutix currently has a consensus rating of “Hold” and an average target price of $20.67.
Ocular Therapeutix (NASDAQ:OCUL) traded up $0.04 during midday trading on Monday, hitting $4.87. 200,600 shares of the company traded hands, compared to its average volume of 300,450. The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39. Ocular Therapeutix has a twelve month low of $3.30 and a twelve month high of $11.79. The company has a market capitalization of $140.93, a PE ratio of -2.15 and a beta of 1.32.
Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, hitting analysts’ consensus estimates of ($0.54). The firm had revenue of $523.00 million during the quarter, compared to analysts’ expectations of $0.52 million. Ocular Therapeutix had a negative net margin of 3,241.19% and a negative return on equity of 126.31%. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.39) earnings per share. sell-side analysts predict that Ocular Therapeutix will post -2.37 earnings per share for the current year.
In other news, Chairman Amarpreet Sawhney bought 19,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was bought at an average price of $5.18 per share, for a total transaction of $98,420.00. Following the completion of the purchase, the chairman now owns 696,390 shares of the company’s stock, valued at approximately $3,607,300.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Antony C. Mattessich bought 21,000 shares of the business’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average price of $4.29 per share, with a total value of $90,090.00. Following the purchase, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $90,090. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 69,500 shares of company stock valued at $304,781. Corporate insiders own 26.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Ocular Therapeutix (OCUL) Stock Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-ocular-therapeutix-ocul-stock-price/1798784.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with Analyst Ratings Network's FREE daily email newsletter.